2-(4-hydroxybenzoyl)benzoic acid methyl ester | 21147-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-hydroxybenzoyl)benzoic acid methyl ester
• 英文别名: methyl 2-(4-hydroxybenzoyl) benzoate；methyl 2-(4-hydroxybenzoyl)benzoate；2-(4-hydroxy-benzoyl)-benzoic acid methyl ester；2-(4-Hydroxy-benzoyl)-benzoesaeure-methylester
• CAS: 21147-23-9
• 化学式: C₁₅H₁₂O₄
• 分子量: 256.258
• InChiKey: IKMDAJBBMNDKJY-UHFFFAOYSA-N

物化性质

• 沸点：
  415.4±25.0 °C(Predicted)
• 密度：
  1.256±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2918990090
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxybenzoyl)benzoic acid methyl ester 在 水 、 caesium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙腈 为溶剂， 反应 4.0h， 生成 2-(4-(Prop-2-yn-1-yloxy)benzoyl)benzoic acid
  参考文献：
  名称：

  Synthesis of dibenzo-[b,f][1,5]diazocine-based hosts and their assembly behaviors with C60

  摘要：

  DOI：

  10.1016/j.tetlet.2014.04.094
• 作为产物：
  描述：

  酚酞 在 氢氧化钾 、 盐酸羟胺 、 乙酰氯 作用下， 反应 16.0h， 生成 2-(4-hydroxybenzoyl)benzoic acid methyl ester
  参考文献：
  名称：

  Small-Molecule Inhibitors of the MDM2-p53 Protein−Protein Interaction Based on an Isoindolinone Scaffold

  摘要：

  From a set of weakly potent lead compounds, using in silico screening and small library synthesis, a series of 2-alkyl-3-aryl-3-alkoxyisoindolinones has been identified as inhibitors of the MDM2-p53 interaction. Two of the most potent compounds, 2-benzyl-3-(4-chlorophenyl)-3-(3-hydroxypropoxy)-2,3-dihydroisoindol-1-one (76; IC50 = 15.9 +/- 0.8 mu M) and 3-(4-chlorophenyl)-3-(4-hydroxy-3,5-dimethoxybenzyloxy)-2-propyl-2,3-dihydroisoindol-1-one (79; IC50) 5.3 (0.9 mu M), induced p53-dependent gene transcription, in a dose-dependent manner, in the MDM2 amplified, SJSA human sarcoma cell line.

  DOI：

  10.1021/jm0601194

文献信息

• Visible Light Copper Photoredox-Catalyzed Aerobic Oxidative Coupling of Phenols and Terminal Alkynes: Regioselective Synthesis of Functionalized Ketones via C≡C Triple Bond Cleavage
  作者：Arunachalam Sagadevan、Vaibhav Pramod Charpe、Ayyakkannu Ragupathi、Kuo Chu Hwang

  DOI：10.1021/jacs.6b13113

  日期：2017.3.1

  Direct oxidative coupling of phenols and terminal alkynes was achieved at room temperature by a visible-light-mediated copper-catalyzed photoredox process. This method allows regioselective synthesis of hydroxyl-functionalized aryl and alkyl ketones from simple phenols and phenylacetylene via C≡C triple bond cleavage. 47 examples were presented. From a synthetic perspective, this protocol offers an

  通过可见光介导的铜催化光氧化还原过程，在室温下实现了酚类和末端炔烃的直接氧化偶联。该方法允许通过 C≡C 三键断裂从简单的苯酚和苯乙炔区域选择性合成羟基官能化的芳基酮和烷基酮。展示了 47 个例子。从合成的角度来看，该协议为制备药物（如匹托苯和非诺贝特）提供了一种有效的合成途径。
• [EN] ISOINDOLIN-1-ONE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOINDOLIN-1-ONE
  申请人：CANCER REC TECH LTD

  公开号：WO2006024837A1

  公开（公告）日：2006-03-09

  A compound of formula (1) or a prodrug and/or pharmaceutically acceptable salt thereof, wherein X is selected from O, N or S; R1 is selected from hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is selected from hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is selected from hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are independently selected from H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, halo, CF3, NH2, NO2, COOH, C=0.

  式（1）的化合物或其前药和/或药用可接受的盐，其中X选择自O、N或S；R1选择自氢、卤素、羟基、取代或未取代的烷基、取代或未取代的羟基烷基、取代或未取代的烷基胺、烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基或杂环芳基；R2选择自氢、卤素、羟基、取代或未取代的烷基、取代或未取代的羟基烷基、取代或未取代的烷基胺、烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基或杂环芳基；R3选择自氢、卤素、羟基、取代或未取代的合金取代或未取代的羟基烷基、取代或未取代的烷基胺烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基或杂环芳基；R4-R7，用于表示独立选择自H、OH、烷基、烷氧基、烷基胺、羟基烷基、卤素、CF3、NH2、NO2、COOH、C=0的基团R4、R5、R6和R7。
• Palladium-Catalyzed Environmentally Benign Acylation
  作者：Basuli Suchand、Gedu Satyanarayana

  DOI：10.1021/acs.joc.6b01064

  日期：2016.8.5

  zed carbonylations involved either toxic carbon monoxide (CO) gas as carbonylating agent or functional-group-assisted ortho sp2 C–H activation (i.e., ortho acylation) or carbonylation by activation of the carbonyl group (i.e., via the formation of enamines). Contradicting these methods, here we describe an environmentally benign process, [Pd]-catalyzed direct carbonylation starting from simple and

  最近的研究趋势已趋向于开发使用无毒试剂的有效策略。较早报道的过渡金属催化的羰基化涉及有毒的一氧化碳（CO）气体作为羰基化剂或官能团辅助的邻位sp 2C–H活化（即邻位酰化）或通过羰基活化（即通过形成烯胺）进行羰基化。与这些方法相反，在此我们描述了一种环境友好的过程，即[Pd]催化的直接羰基化反应，该反应从简单的可商购的碘代芳烃和醛开始，用于合成多种酮。此外，该方法包括使碘代芳烃与醛直接偶联而不活化羰基，也无需直接进行基团辅助。重要的是，该策略已成功地应用于合成正丁基邻苯二甲酸酯和匹托芬酮。
• Non-Peptidic Small-Molecule Inhibitors of the Single-Chain Hepatitis C Virus NS3 Protease/NS4A Cofactor Complex Discovered by Structure-Based NMR Screening
  作者：Daniel F. Wyss、Ashok Arasappan、Mary M. Senior、Yu-Sen Wang、Brian M. Beyer、F. George Njoroge、Mark A. McCoy

  DOI：10.1021/jm0305117

  日期：2004.5.1

  binding sites, were linked together producing competitive inhibitors of the HCV NS3 protease with potencies in the micromolar range. This example illustrates that the low molecular weight scaffolds discovered from structure-based NMR screening can be optimized with focused structure-guided chemistry to produce potent nonpeptidic small-molecule inhibitors of the HCV NS3 protease.

  基于NMR的定制片段库筛选确定了16个小分子命中，它们与丙型肝炎病毒（HCV）的NS4A结合NS3蛋白酶的底物结合位点弱结合（K（D）约100 microM至10 mM）。通过NMR和生化数据的结合来评估SAR的五类NMR命中物的类似物，并且在大多数情况下，具有改进的效力（K（D）约K（I）约40 microM至1 mM）的优化命中。NMR化学位移扰动数据用于确定这五个类似物系列中活性位点定向支架的结合位置和方向。这些支架中的两个在近端S1-S3和S2'底物结合位点处结合酶，连接在一起，产生具有微摩尔范围效价的HCV NS3蛋白酶竞争性抑制剂。
• Isoindolin-1-One Derivatives
  申请人：Willems Hendrika Maria Gerarda

  公开号：US20080261917A1

  公开（公告）日：2008-10-23

  A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R 1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R 2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R 3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R 4 -R 7 , is used to represent groups R 4 , R 5 , R 6 and R 7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, halo, CF 3 , NH 2 , NO 2 , COOH, C=0.

  该化合物的化学式为，或其前体药物和/或其药学上可接受的盐，其中X为O、N或S；R1为氢、卤、羟基、取代或未取代的烷基、取代或未取代的羟基烷基、取代或未取代的烷基胺、烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基烷基或杂环芳基烷基；R2为氢、卤、羟基、取代或未取代的烷基、取代或未取代的羟基烷基、取代或未取代的烷基胺、烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基烷基或杂环芳基烷基；R3为氢、卤、羟基、取代或未取代的烷基、取代或未取代的羟基烷基、取代或未取代的烷基胺、烷氧基、取代或未取代的芳基或杂环芳基、取代或未取代的芳基烷基或杂环芳基烷基；R4-R7用于代表R4、R5、R6和R7的基团，其为H、OH、烷基、烷氧基、烷基胺、羟基烷基、卤、CF3、NH2、NO2、COOH、C=0。